$3.06 Billion is the total value of BRAIDWELL LP's 82 reported holdings in Q2 2023. The portfolio turnover from Q1 2023 to Q2 2023 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| New | ASCENDIS PHARMA A/Snote 2.250% 4/0 | $113,150,000 | – | 124,000,000 | +100.0% | 3.70% | – | |
| KROS | New | KEROS THERAPEUTICS INC | $45,960,496 | – | 1,143,865 | +100.0% | 1.50% | – |
| BSX | New | BOSTON SCIENTIFIC CORP | $38,785,235 | – | 717,050 | +100.0% | 1.27% | – |
| VRDN | New | VIRIDIAN THERAPEUTICS INC | $28,697,877 | – | 1,206,300 | +100.0% | 0.94% | – |
| MRVI | New | MARAVAI LIFESCIENCES HLDGS I | $22,432,421 | – | 1,804,700 | +100.0% | 0.73% | – |
| CGEM | New | CULLINAN ONCOLOGY INC | $20,539,387 | – | 1,908,865 | +100.0% | 0.67% | – |
| RAPT | New | RAPT THERAPEUTICS INC | $18,408,280 | – | 984,400 | +100.0% | 0.60% | – |
| TMO | New | THERMO FISHER SCIENTIFIC INC | $14,243,775 | – | 27,300 | +100.0% | 0.46% | – |
| RYTM | New | RHYTHM PHARMACEUTICALS INC | $13,902,505 | – | 843,087 | +100.0% | 0.45% | – |
| New | INTEGRA LIFESCIENCES HLDGS Cnote 0.500% 8/1 | $13,311,000 | – | 14,500,000 | +100.0% | 0.44% | – | |
| DHR | New | DANAHER CORPORATION | $13,296,000 | – | 55,400 | +100.0% | 0.43% | – |
| RGEN | New | REPLIGEN CORP | $13,014,320 | – | 92,000 | +100.0% | 0.42% | – |
| New | ACELYRIN INC | $10,450,000 | – | 500,000 | +100.0% | 0.34% | – | |
| GH | New | GUARDANT HEALTH INC | $9,666,000 | – | 270,000 | +100.0% | 0.32% | – |
| SGEN | New | SEAGEN INC | $8,178,973 | – | 42,497 | +100.0% | 0.27% | – |
| AGEN | New | AGENUS INC | $7,516,688 | – | 4,697,930 | +100.0% | 0.25% | – |
| New | CUTERA INCnote 2.250% 6/0 | $7,202,906 | – | 11,500,000 | +100.0% | 0.24% | – | |
| ATEC | New | ALPHATEC HLDGS INC | $457,249 | – | 25,431 | +100.0% | 0.02% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| GUARDANT HEALTH INC | 4 | Q3 2023 | 6.3% |
| EXACT SCIENCES CORP | 4 | Q3 2023 | 4.4% |
| NOVOCURE LTD | 4 | Q3 2023 | 3.9% |
| NANOSTRING TECHNOLOGIES INC | 4 | Q3 2023 | 4.0% |
| NEVRO CORP | 4 | Q3 2023 | 3.4% |
| BRIDGEBIO PHARMA INC | 4 | Q3 2023 | 3.5% |
| ALPHATEC HLDGS INC | 4 | Q3 2023 | 3.6% |
| GLAUKOS CORP | 4 | Q3 2023 | 3.0% |
| VAXCYTE INC | 4 | Q3 2023 | 2.8% |
| XENON PHARMACEUTICALS INC | 4 | Q3 2023 | 2.5% |
View BRAIDWELL LP's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G | 2023-02-14 |
| SC 13G | 2023-02-14 |
View BRAIDWELL LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.